Open main menu
Home
Random
Recent changes
Special pages
Community portal
Preferences
About Wikipedia
Disclaimers
Incubator escapee wiki
Search
User menu
Talk
Dark mode
Contributions
Create account
Log in
Editing
Primary biliary cholangitis
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
===Itching=== Pruritus is a common symptom in people with PBC. First-line treatment of pruritus consists of anion-exchange resins, such as [[cholestyramine]], [[colestipol]], or [[colesevalam]].<ref name=AASLD_2018 /> These anion-exchange resins are nonabsorbed, highly positively charged substances that bind bile acids, which are negatively charged anions.<ref name=AASLD_2018 /> Anion-exchange resins relieve itching caused by excess bile acids in circulation by binding bile acids in the gut and facilitating elimination. Bloating or constipation may occur with anion-exchange resins.<ref name=AASLD_2018 /> Cholestyramine may affect absorption of [[Ursodeoxycholic acid|UDCA]]; if cholestyramine is necessary, it should be taken at least 60 minutes before or 4 hours after UDCA is taken.<ref name=AASLD_2018 /> Treatment options for pruritus that does not improve with anion-exchange resins include: [[rifampicin]], [[naltrexone]], or [[sertraline]].<ref name=AASLD_2018 /> Rifampicin may rarely cause drug induced liver injury and should be avoided if serum bilirubin is elevated (greater than 2.5 mg/dL). Liver enzymes should be monitored after starting rifampin.<ref name=EASL_2017 /> Rifampicin induces enzymes, resulting in numerous potential drug-drug interactions.<ref name=AASLD_2018 /> Opioid antagonists may cause a self-limited opioid withdrawal like reaction, with abdominal pain, elevated blood pressure, tachycardia, goose bumps, nightmares, and depersonalization.<ref name=AASLD_2018 /> To avoid such reactions, the dose should start low and gradually be increased.<ref name=AASLD_2018 />
Edit summary
(Briefly describe your changes)
By publishing changes, you agree to the
Terms of Use
, and you irrevocably agree to release your contribution under the
CC BY-SA 4.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)